## 1 page CV

Axel Finckh, MD	POSITION TITLE - Associate Professor, Rheumatology, Dept. of Medical		
Rheumatology Division Geneva University Hospital CH - 1211 Geneva 14, Switzerland	Specialties, Geneva University Hospital (HUG), CH - Consultant in Epidemiology, Clinical Research Center, HUG, CH		

## **EDUCATION/TRAINING**

INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
University of Geneva, Switzerland	M.D.	1992	Medicine
Public Hospitals of Paris, France		1992-94	Residency in Internal Med.
University of Geneva, Switzerland	Doctorate	1997	Epidemiology & Rheumatology
Geneva University Hospital, Switzerland		1994-00	Residency Int. Med. & Rheum
University Hospital of Vaud (CHUV), Switzerland		2000-02	Senior resident, Rheumatology
Harvard School of Public Health, USA	M.S.	2004	Epidemiology
Brigham and Women's Hospital, Boston, USA		2002-05	Clinical research
Geneva University Hospital, Switzerland	PD	2005-cont'd	Faculty at Rheumatology Div.

## A. Person Statement

Finckh leads clinical research in the Division of Rheumatology at the University of Geneva. He trained in Internal Medicine and Rheumatology in Paris, Geneva and Lausanne and received his MSc in Epidemiology from Harvard School of Public Health. Finckh chairs the Scientific Commission of the Swiss Rheumatoid Arthritis cohort (SCQM-RA) and the EULAR Study Group of Epidemiology. His research includes the identification of modifiable risk factors in rheumatoid arthritis (RA), impact of early therapeutic interventions in RA, comparative effectiveness research and identification of pre-clinical phase of RA. He is leading a multicenter study entitled "evaluation of a novel screening strategy for rheumatoid arthritis" in Switzerland.

## C. Selected, recent publications

- Alpizar-Rodriguez D,\* Lesker TR,\* Gronow A, Gilbert B, Raemy E, Lamacchia C, Gabay C, **Finckh A**,# Strowig T# (\*# equally contributed). "Prevotella copri in individuals at risk for rheumatoid Arthritis". Annals of the Rheumatic Diseases 2019;78:590-593.
- D. Alpizar-Rodriguez, (...) and **A. Finckh**. "Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis. Results from the SCQM cohort." Rheumatology (Oxford). 2018 Oct 31, 10.1093/rheumatology/key311
- Loutan L; Alpizar Rodriguez D; **Finckh A,** Mombelli A, and Giannopoulou E. "Periodontal status correlates with anti-citrullinated protein antibodies (ACPAs) in first degree relatives of individuals with rheumatoid arthritis". J Clin Periodontol. 2019 Apr 26.
- Lauper K, Courvoisier DS, (...) **Finckh A**, and Gabay C. "Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis". Arthritis Care Res (Hoboken). 2018 Dec;70(12):1756-1763
- D Alpizar-Rodriguez; R Müller; B Moller; (...) and **A Finckh**. "Female hormonal factors and the development of anticitrullinated protein antibodies in women at risk of rheumatoid arthritis (RA)" Rheumatology (Oxford). 2017 Sep 1;56(9):1579-1585
- *M. V. Beers-Tas, M. Ter Wee, (...), A. Finckh, D. Courvoisier, Raza, D.V. Schaardenburg.* "Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire, a EULAR project. In press in RMD open
- **Finckh A,** Escher M, Liang MH, and Bansback N. Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences. Curr Rheumatol Rep. 2016 Aug;18(8):51
- D. Alpizar-Rodriguez, C. Lamacchia, (...) C. Gabay, and **A. Finckh**. "The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis". Clin Rheumatol. 2017 Mar;36(3):677-682
- ST, Huttner A, Zinser ME, Njuguna P, Finckh A, (...), Addo MM, Siegrist CA.
   Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe Preliminary Report. N Engl J Med. 2015 Apr 1